AWARENESS ABOUT MEDICAL APPLICATIONS OF QL-47 AMONG DENTAL STUDENTS
DOI:
https://doi.org/10.61841/e63py873Keywords:
Awareness, QL 47, dental studentsAbstract
QL47, a Bruton tyrosine kinase inhibitor, is a host-targeted, small-molecule antiviral that inhibits steady-state viral protein expression. This small molecule broadly inhibits both viral and host protein synthesis and targets a translation step specific to eukaryotic cells and has the potential to be used as antiviral medication. The aim of the study was to assess the awareness about medical applications of QL-47 among dental students. This was a questionnaire-based cross-sectional type of study comprising 100 dental college students in Chennai. A self-designed questionnaire with 10 questions eliciting the knowledge and awareness about QL 47 therapy among dental college students. Questionnaires were circulated through an online website survey planet The questions explored the awareness of QL 47 therapy, indications, contraindications, mechanism of action, and side effects. After the responses were received from 100 participants, data was collected and analyzed. 5% were aware of QL 47 therapy. 3% were aware of the mechanism of action of QL 47 therapy. 4% were aware of the indications of QL 47 therapy. 3% were aware of the QL 47 therapy. 3% were aware of the side effects of QL 47 therapy . The awareness about QL 47 in medical applications and managing viral infections was less among dental students. Increased awareness and educational programs should be initiated to spread knowledge about QL 47 therapy.
Downloads
References
1. Ahammad, F., Tengku Rogayah Tengku, Mohamed, M., Tanbin, S., & Fuad, F. A. A. (2019). Contemporary
Strategies and Current Trends in Designing Antiviral Drugs against Dengue Fever via Targeting Host-Based
Approaches. In Microorganisms (Vol. 7, Issue 9, p. 296). https://doi.org/10.3390/microorganisms7090296
2. Erlanson, D. A., Jahnke, W., Mannhold, R., Kubinyi, H., & Folkers, G. (2016). Fragment-based Drug
Discovery: Lessons and Outlook. John Wiley & Sons.
3. Hopkins, B. T., Bame, E., Bell, N., Bohnert, T., Bowden-Verhoek, J. K., Bui, M., Cancilla, M. T., Conlon,
P., Cullen, P., Erlanson, D. A., Fan, J., Fuchs-Knotts, T., Hansen, S., Heumann, S., Jenkins, T. J., Marcotte,
D., McDowell, B., Mertsching, E., Negrou, E., … Zhong, M. (2019). Optimization of novel reversible
Bruton’s tyrosine kinase inhibitors were identified using tethering-fragment-based screens. In Bioorganic &
Medicinal Chemistry (Vol. 27, Issue 13, pp. 2905–2913). https://doi.org/10.1016/j.bmc.2019.05.021
4. Hu, H., Li, M., Wu, D., Li, Z., Miao, R., Liu, Y., & Gong, P. (2019). Design, synthesis and biological
evaluation of novel aryl-acrylic derivatives as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors. In
Bioorganic & Medicinal Chemistry (Vol. 27, Issue 14, pp. 3135–3144).
https://doi.org/10.1016/j.bmc.2019.05.048
5. Liang, Y., de Wispelaere, M., Carocci, M., Liu, Q., Wang, J., Yang, P. L., & Gray, N. S. (2017). Structure—
Activity Relationship Study of QL47: A Broad-Spectrum Antiviral Agent. In ACS Medicinal Chemistry
Letters (Vol. 8, Issue 3, pp. 344–349). https://doi.org/10.1021/acsmedchemlett.7b00008
6. Wispelaere, M. de, de Wispelaere, M., Carocci, M., Burri, D. J., Neidermyer, W. J., Olson, C. M.,
Roggenbach, I., Liang, Y., Wang, J., Whelan, S. P. J., Gray, N. S., & Yang, P. L. (2020). A broad-spectrum
The antiviral molecule QL47 selectively inhibits eukaryotic translation. In Journal of Biological Chemistry
(Vol. 295, Issue 6, pp. 1694–1703). https://doi.org/10.1074/jbc.ra119.011132
7. Wispelaere, M. de, de Wispelaere, M., Carocci, M., Liang, Y., Liu, Q., Sun, E., Vetter, M. L., Wang, J.,
Gray, N. S., & Yang, P. L. (2017). Discovery of host-targeted covalent inhibitors of dengue virus. In
Antiviral Research (Vol. 139, pp. 171–179). https://doi.org/10.1016/j.antiviral.2016.12.017
8. Wu, H., Hu, C., Wang, A., Weisberg, E. L., Chen, Y., Yun, C.-H., Wang, W., Liu, Y., Liu, X., Tian, B.,
Wang, J., Zhao, Z., Liang, Y., Li, B., Wang, L., Wang, B., Chen, C., Buhrlage, S. J., Qi, Z., … Liu, Q.
(2016). Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia. In Leukemia (Vol. 30, Issue
1, pp. 173–181). https://doi.org/10.1038/leu.2015.180
9. Wu, H., Wang, W., Liu, F., Weisberg, E. L., Tian, B., Chen, Y., Li, B., Wang, A., Wang, B., Zhao, Z.,
McMillin, D. W., Hu, C., Li, H., Wang, J., Liang, Y., Buhrlage, S. J., Liang, J., Liu, J., Yang, G., … Gray,
N. S. (2014). Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma. In ACS Chemical
Biology (Vol. 9, Issue 5, pp. 1086–1091). https://doi.org/10.1021/cb4008524
10. Zhai, Z., Li, R., Bai, X., Ning, X., Lin, Z., Zhao, X., Jin, Y., & Yin, Y. (2019). Design, synthesis and
biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK
inhibitors. In Bioorganic & Medicinal Chemistry (Vol. 27, Issue 18, pp. 4124–4142).
https://doi.org/10.1016/j.bmc.2019.07.043
11. Zou, Y., Xiao, J., Tu, Z., Zhang, Y., Yao, K., Luo, M., Ding, K., Zhang, Y., & Lai, Y. (2016). Structure-based discovery of novel 4,5,6-trisubstituted pyrimidines as potent covalent Bruton’s tyrosine kinase
inhibitors. In Bioorganic & Medicinal Chemistry Letters (Vol. 26, Issue 13, pp. 3052–3059).
Downloads
Published
Issue
Section
License
Copyright (c) 2020 AUTHOR
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
